乳腺癌新辅助治疗的进展

Progress and challenge of neoadjuvant therapy for breast cancer

随着医疗技术的发展,乳腺癌的治疗已从局部治疗时代进入化疗、放疗、内分泌治疗、分子靶向治疗相结合的综合治疗时代,新辅助治疗因其具有使乳腺原发肿瘤及腋窝淋巴结降期、提高保乳率、预测药物敏感性等优势,在临床中的应用日渐广泛。随着乳腺癌分子分型的出现,新辅助治疗也从最初的新辅助化疗转变为新辅助化疗、新辅助内分泌治疗及新辅助靶向治疗联合的综合治疗模式。我们从乳腺癌不同分子分型的新辅助治疗方案、疗效评估、治疗后手术方式的选择等方面进行综述。

With the development of medical technology,the treatment of breast cancer has entered into a comprehensive treatment age which combines chemotherapy,radiotherapy,endocrine therapy and molecular targeting therapy from the time of local treatment. Neoadjuvant therapy has been widely applied in clinic due to many advantages,such as lowering the primary breast tumor and axillary lymph node,improving breast conserving rate and predicting drug sensitivity. With the emergence of molecular typing of breast cancer,neoadjuvant therapy has changed from primary neoadjuvant chemotherapy to the comprehensive treatment with neoadjuvant chemotherapy,neoadjuvant endocrine therapy and neoadjuvant targeted therapy. Here is a review of the progress of neoadjuvant therapy,evaluation of curative effect,selection of operation mode and challenges of neoadjuvant therapy from different molecular typing of breast cancer.